Patents by Inventor Ingrid Choong
Ingrid Choong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240082360Abstract: Methods of treating a hepatitis delta virus (HDV) infection in a human subject are provided. In some embodiments, the method comprises subcutaneously administering to the subject a therapeutically effective amount of pegylated interferon lambda-1a in combination with lonafarnib and ritonavir for at least 24 weeks. In another aspect, provided herein are methods of treating HDV infections in a subject, comprising the following drug regimen subcutaneously administering to the subject a therapeutically effective amount of pegylated interferon lambda-1a once per week, and administering lonafarnib and ritonavir daily until one or more of a sustained rHDV viral load is reached, or a decrease in HDV RNA to undetectable levels, or for 12 weeks, or for 24 weeks, or for 48 weeks.Type: ApplicationFiled: October 15, 2020Publication date: March 14, 2024Inventors: Ingrid CHOONG, Jeffrey S. GLENN
-
Patent number: 11884657Abstract: Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole or a 5-heteroaryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribavirin, and the like.Type: GrantFiled: July 9, 2021Date of Patent: January 30, 2024Assignees: The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of CaliforniaInventors: Jeffrey S. Glenn, Michael A. Gelman, Brandon Tavshanjian, Kevan Shokat, Ingrid Choong, Mark Smith
-
Patent number: 11793793Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.Type: GrantFiled: March 18, 2022Date of Patent: October 24, 2023Assignee: Eiger Biopharmaceuticals, Inc.Inventors: David A. Cory, Ingrid Choong, Jeffrey S. Glenn
-
Publication number: 20230285510Abstract: Methods of treating a coronavirus infection in a human subject are provided. In some embodiments, the method comprises subcutaneously administering to the subject a therapeutically effective amount of pegylated interferon lambda-1a.Type: ApplicationFiled: February 5, 2021Publication date: September 14, 2023Applicant: Eiger Biopharmaceuticals, Inc.Inventors: Jeffrey GLENN, Ingrid CHOONG, Colin HISLOP
-
Publication number: 20230201308Abstract: Methods of treating a coronavirus infection in a human subject are provided. In some embodiments, the method comprises subcutaneously administering to the subject a therapeutically effective amount of pegylated interferon lambda-1a.Type: ApplicationFiled: August 11, 2022Publication date: June 29, 2023Applicant: Eiger Biopharmaceuticals, Inc.Inventors: Jeffrey GLENN, Ingrid CHOONG, Colin HISLOP
-
Publication number: 20230046607Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.Type: ApplicationFiled: March 18, 2022Publication date: February 16, 2023Inventors: David A. Cory, Ingrid Choong, Jeffrey S. Glenn
-
Patent number: 11311519Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.Type: GrantFiled: August 18, 2020Date of Patent: April 26, 2022Assignee: Eiger BioPharmaceuticals, Inc.Inventors: David A. Cory, Ingrid Choong, Jeffrey S. Glenn
-
Publication number: 20220023287Abstract: Tipifarnib or a tipifarnib derivative is used to treat HDV infection as a monotherapy or in combination with an interferon and/or boosting agent such as a CYP3A4 inhibitor such as ritonavir and cobicistat.Type: ApplicationFiled: March 10, 2021Publication date: January 27, 2022Applicant: Eiger BioPharmaceuticals, Inc.Inventors: David Cory, Ingrid Choong, Jeffrey S. Glenn
-
Publication number: 20220017507Abstract: Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole or a 5-heteroaryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribivarin, and the like.Type: ApplicationFiled: July 9, 2021Publication date: January 20, 2022Inventors: Jeffrey S. Glenn, Michael A. Gelman, Brandon Tavshanjian, Kevan Shokat, Ingrid Choong, Mark Smith
-
Patent number: 11091472Abstract: Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole or a 5-hetereoaryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribivarin, and the like.Type: GrantFiled: February 24, 2017Date of Patent: August 17, 2021Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Jeffrey S. Glenn, Michael A. Gelman, Brandon Tavshanjian, Kevan Shokat, Ingrid Choong, Mark Smith
-
Publication number: 20210187073Abstract: Methods of treating a hepatitis delta virus (HDV) infection in a human subject are provided. In some embodiments, the method comprises subcutaneously administering to the subject a therapeutically effective amount of pegylated interferon lambda-1a for at least 48 weeks.Type: ApplicationFiled: August 23, 2019Publication date: June 24, 2021Inventors: Ingrid CHOONG, Eduardo Bruno MARTINS
-
Publication number: 20200375955Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.Type: ApplicationFiled: August 18, 2020Publication date: December 3, 2020Inventors: David A. Cory, Ingrid Choong, Jeffrey S. Glenn
-
Patent number: 10828283Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.Type: GrantFiled: August 1, 2018Date of Patent: November 10, 2020Assignee: Eiger Biopharmaceuticals, Inc.Inventors: David A. Cory, Ingrid Choong, Jeffrey S. Glenn
-
Patent number: 10428060Abstract: Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole or a 5-hetereoaryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribivarin, and the like.Type: GrantFiled: February 9, 2018Date of Patent: October 1, 2019Assignees: The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of CaliforniaInventors: Jeffrey S. Glenn, Michael A. Gelman, Brandon Tavshanjian, Kevan Shokat, Ingrid Choong
-
Publication number: 20190167646Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.Type: ApplicationFiled: August 1, 2018Publication date: June 6, 2019Applicant: Eiger BioPharmaceuticals, Inc.Inventors: David A. Cory, Ingrid Choong, Jeffrey S. Glenn
-
Publication number: 20190062323Abstract: Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole or a 5-hetereoaryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribivarin, and the like.Type: ApplicationFiled: February 24, 2017Publication date: February 28, 2019Inventors: Jeffrey S. Glenn, Michael A. Gelman, Brandon Tavshanjian, Kevan Shokat, Ingrid Choong, Mark Smith
-
Publication number: 20180338993Abstract: Tipifarnib or a tipifarnib derivative is used to treat HDV infection as a monotherapy or in combination with an interferon and/or boosting agent such as a CYP3A4 inhibitor such as ritonavir and cobicistal. This invention arises in part out of the surprising discoveries that not all prenyltransferase inhibitors are efficacious in treating HDV infection and that tipifarnib (Rl 15777) and tipifarnib derivatives such as R208176 can be administered at a dose efficacious in humans. This invention accordingly provides a method of inhibiting HDV replication in a human subject known to be co-infected with HBV and HDV by administering a therapeutically effective dose of tipifarnib, R208176 and other therapeutically effective tipifarnib derivatives and pharmaceutically acceptable salts and other forms.Type: ApplicationFiled: December 3, 2015Publication date: November 29, 2018Applicant: Eiger BioPharmaceuticals, Inc.Inventors: David Cory, Ingrid Choong, Jeffrey S. Glenn
-
Patent number: 10076512Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.Type: GrantFiled: October 26, 2016Date of Patent: September 18, 2018Assignee: Eiger BioPharmaceuticals, Inc.Inventors: David A. Cory, Ingrid Choong, Jeffrey S. Glenn
-
Publication number: 20180170924Abstract: Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole or a 5-hetereoaryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribivarin, and the like.Type: ApplicationFiled: February 9, 2018Publication date: June 21, 2018Inventors: Jeffrey S. Glenn, Michael A. Gelman, Brandon Tavshanjian, Kevan Shokat, Ingrid Choong, Mark Smith
-
Patent number: 9926309Abstract: Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole or a 5-hetereoaryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribivarin, and the like.Type: GrantFiled: February 26, 2016Date of Patent: March 27, 2018Assignees: The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of CaliforniaInventors: Jeffrey S. Glenn, Michael A. Gelman, Brandon Tavshanjian, Kevan Shokat, Ingrid Choong, Mark Smith